Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Pipeline Review, H1 2017

  • ID: 4318707
  • Report
  • 34 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Forma Therapeutics Inc
  • Incyte Corp
  • MORE
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Pipeline Review, H1 2017

Summary:

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Bromodomain testis-specific protein is a protein encoded by the BRDT gene. It plays a role in meiotic and post-meiotic cells by binding to acetylated histones at the promoter of specific meiotic and post-meiotic genes, facilitating their activation at the appropriate time. It binds to hyperacetylated histones and participates in their general removal from DNA.

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase II and Phase I stages are 1 and 4 respectively. Report covers products from therapy areas Oncology which include indications Myelodysplastic Syndrome, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Multiple Myeloma (Kahler Disease), Myelofibrosis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myeloproliferative Disorders, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Refractory Multiple Myeloma and Relapsed Multiple Myeloma.

The latest report Bromodomain Testis Specific Protein - Pipeline Review, H1 2017, outlays comprehensive information on the Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT)
  • The report reviews Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Forma Therapeutics Inc
  • Incyte Corp
  • MORE
  1. Introduction
  2. Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Overview
  3. Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Therapeutics Assessment
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Companies Involved in Therapeutics Development
  13. F. Hoffmann-La Roche Ltd
  14. Forma Therapeutics Inc
  15. Incyte Corp
  16. Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Drug Profiles
  17. CPI-0610 - Drug Profile
  18. Product Description
  19. Mechanism Of Action
  20. R&D Progress
  21. FT-1101 - Drug Profile
  22. Product Description
  23. Mechanism Of Action
  24. R&D Progress
  25. INCB-54329 - Drug Profile
  26. Product Description
  27. Mechanism Of Action
  28. R&D Progress
  29. RG-6146 - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. ZEN-3694 - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Discontinued Products
  38. Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Product Development Milestones
  39. Featured News & Press Releases
  40. Jun 05, 2017: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention
  41. Dec 14, 2016: Zenith Announces Initiation of Phase 1b Clinical Combination Trial for ZEN-3694
  42. Jun 15, 2016: Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and Corporate Update Webcast Details
  43. Jan 12, 2016: FORMA Therapeutics Enrolls First Patient in Phase 1 Study of FT-1101 in Advanced Hematological Malignancies
  44. Nov 20, 2013: Tensha Therapeutics Announces First Clinical Trial of BET Bromodomain Inhibitor TEN-010 for Treatment of Cancer
  45. Sep 10, 2013: Constellation Pharmaceuticals Initiates Clinical Development of CPI-0610, a Novel BET Protein Bromodomain Inhibitor, in Patients with Lymphoma
  46. Nov 29, 2012: Cancer Drug Shows Promise In Eradicating Latent HIV Infection, Research Shows
  47. Aug 16, 2012: Researchers Develop Potential Male Contraceptive Pill
  48. Appendix
  49. Methodology
  50. Coverage
  51. Secondary Research
  52. Primary Research
  53. Expert Panel Validation
  54. Contact Us
  55. Disclaimer
List of Tables
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Products under Development by Companies, H1 2017 (Contd..1), H1
  7. Number of Products by Stage and Mechanism of Actions, H1
  8. Number of Products by Stage and Route of Administration, H1
  9. Number of Products by Stage and Molecule Type, H1
  10. Pipeline by F. Hoffmann-La Roche Ltd, H1
  11. Pipeline by Forma Therapeutics Inc, H1
  12. Pipeline by Incyte Corp, H1
  13. Discontinued Products, H1
List of Figures
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Top 10 Indications, H1
  3. Number of Products by Stage and Mechanism of Actions, H1
  4. Number of Products by Routes of Administration, H1
  5. Number of Products by Stage and Routes of Administration, H1
  6. Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • F. Hoffmann-La Roche Ltd
  • Forma Therapeutics Inc
  • Incyte Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll